Press Releases

Year

March 30, 2021

Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million , respectively Received FDA approval and subsequently introduced Upneeq ® (oxymetazoline hydrochloride ophthalmic solution, 0.1%), the first therapeutic for treatment of acquired ptosis in adults Established Upneeq

March 24, 2021

Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021

BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30,

March 3, 2021

Osmotica to Present at Barclays Global Healthcare Conference 2021

BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at

February 18, 2021

Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference

BRIDGEWATER, N.J. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at

February 1, 2021

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) AMENDMENT The Form 8.1(a) dealings disclosure announcement made on January 27, 2020 contained a typographical error in that it referred to dealings in 'relevant securities' by Gregory L.

January 27, 2021

DIRECTOR DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM

January 27, 2021

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR

January 27, 2021

Rule 2.10 Announcement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE January 27, 2021 Osmotica Pharmaceuticals plc BRIDGEWATER, N.J., Jan.

Investor Relations

News

Press Releases

Press Releases

Press Releases